Global Anaplastic Lymphoma Kinase ALK Inhibitors Market & Clinical Trials Insight 2026 Report Highlights:
- Global ALK Inhibitors Market Opportunity: > USD 5 Billion
- US Dominates Global ALK Inhibitors Market Sales: >30%
- Approved ALK Inhibitors: 5 Drugs
- Global & Regional ALK Inhibitors Market Sales Insights (2017-2020)
- Global & Regional ALK Inhibitors Market Opportunity (2021-2026)
- Approved ALK Inhibitors Dosage, Patent, Price & Sales Insights
- Global Clinical Trials Insight By Company, Indication & Phase
The progress made by science and technology in last few decades has led to the identification of several potential targets which can be utilized in the drug development process. The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market. The extensive research activities by the researchers have led to the development of novel anaplastic lymphoma kinase inhibitors which belongs to the class of tyrosine receptor kinase and are used in the management of cancer.
Till now, multiple anaplastic lymphoma kinase inhibitors have been approved by the regulatory authorities and several others are present in clinical pipeline which are expected to enter the market in next few years. The advent of these drugs in the market has overcome the limitations of conventional therapies such as chemotherapy and radiotherapy. The high target ability and specificity of these inhibitors towards the cancer cells has enhanced the survival rates of cancer patients and also improved the quality of life of patients.
Since the approval of first generation anaplastic lymphoma kinase inhibitor in the management of non-small cell lung cancer, researchers have indulge in research activities for the development of next generation inhibitors which can overcome the limitations and can efficiently cross the blood brain barrier for enhanced efficacy. Apart from this, several clinical trials are ongoing to evaluate the efficacy of these drugs in combination with other chemotherapeutic drugs and immune checkpoint inhibitors. The combinational therapy will increase the efficacy of the drug which can better combat the complexity of the cancer.
The global anaplastic lymphoma kinase inhibitor market is going to witness high growth during the forecast period which is mainly attributed to the rise in prevalence of anaplastic lymphoma kinase positive cancers and high research and development activities in this sector. The rates at which conventional therapies are failing will further possess unmet need for the development of novel target therapies which will also drive the growth of the market. In addition to this, the robust clinical pipeline and their increasing application in different cancers will drive the market in coming years.
Despite several advantages of anaplastic lymphoma kinase inhibitors in the management of cancer, there are several factors which restrain the growth of the market. The resistance to the drugs during 1-2 year of the therapy is one of the limiting factors which will act as a barrier to the market. Moreover, the high cost associated with the drug will also limit the availability of the drug and increases the financial toxicity on the patient and their families.
Currently, US holds the top position in the global market and is expected to maintain its position over the forecast period mainly due to the presence of large pharmaceutical sector which actively invest in research and development activities as well as increasing funding by the government to promote research and development. Apart from this, other regions such Europe, Asia-Pacific and Japan are also expanding their markets to secure their position in the global market. The global anaplastic lymphoma kinase inhibitor market is going to witness high growth rate and is expected to double in next 5 years. Furthermore, the market will be flourished with next-generation ALK inhibitors as well as several combinational therapies in wide range of cancers including neuroblastoma, lymphoma and colorectal cancer.
The report “Global Anaplastic Lymphoma Kinase ALK Inhibitors Market & Clinical Trials Insight 2026” includes information about the patent expiration, dosage, price, sales and mechanism of currently approved anaplastic lymphoma kinase inhibitors. In addition to this, several emerging ALK inhibitors along with their clinical trials are also provided in the report.
Table of Contents
1. Introduction to Anaplastic Lymphoma Kinase (ALK) Inhibitors
1.1 Overview
1.2 History of Development
2. ALK Inhibitors as Cancer Therapeutics
2.1 Need of ALK Inhibitors in Cancer Therapy
2.2 ALK - Potential Target in Cancer Therapy
2.3 Mechanism of Action
3. ALK Inhibitors in Lung Cancer
3.1 Role of ALK Inhibitors in Lung Cancer
3.2 On Going Research & Development
4. ALK Inhibitors in Neuroblastoma
4.1 Role of ALK Inhibitor in Neuroblastoma
4.2 On Going Clinical Research
5. ALK Inhibitors in Lymphoma
5.1 Role of ALK in Lymphoma
5.2 On Going Clinical Research
6. ALK Inhibitors in Other Cancers
6.1 ALK Inhibitor in Colorectal Cancer
6.2 ALK in Renal Cell Carcinoma
6.3 ALK Inhibitor in Inflammatory Myofibroblastic Tumor
7. Crizotinib (Xalkori) - Clinical & Commercial Insight
7.1 Overview
7.2 Patents & Assignees
7.3 Dosage & Price Analysis
7.4 Sales Analysis
8. Certinib (Zykadia) - Clinical & Commercial Insight
8.1 Overview
8.2 Patents & Assignees
8.3 Dosage & Price Analysis
9. Alectinib (Alecensa) - Clinical & Commercial Insight
9.1 Overview
9.2 Patents & Assignee
9.3 Dosage & Price Analysis
9.4 Sales Analysis
10. Brigatinib (Alunbrig) - Clinical & Commercial Insight
10.1 Overview
10.2 Patent Information
10.3 Dosage & Price Analysis
10.4 Sales Analysis
11. Lorlatinib (Lorbrena) - Clinical & Commercial Insight
11.1 Overview
11.2 Dosage, Patent & Price Analysis
11.3 Sales Analysis
12. Emerging Novel ALK Inhibitors in Cancer
12.1 Ensartinib
12.2 Entrectinib (RXDX-101)
12.3 TPX-0131
12.4 TQ-B3139
12.5 Belizatinib (TSR-011)
12.6 CEP-37440
12.7 Alkotinib
13. ALK Inhibitor Market Analysis - Clinical Trial Insight
13.1 By Phase
13.2 By Company
13.3 By Country
13.4 By Patient Segment
14. ALK Inhibitors Drug Market
14.1 Current Market Scenario
14.2 Global & Regional Market Analysis
15. ALK Inhibitor Drug Market by Product
15.1 First Generation ALK Inhibitor
15.2 Second Generation ALK Inhibitor
15.3 Third Generation ALK Inhibitor
16. Anaplastic Lymphoma Kinase (ALK) Inhibitors Clinical Trials Insight
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-I/II
16.5 Phase-II
16.6 Phase-III
17. Marketed Anaplastic Lymphoma Kinase (ALK) Inhibitors Clinical Insight
17.1 ALUNBRIG
17.2 Lorbrena/Lorviqua
17.3 Alecensa
17.4 Jikadia/ Zykadia
17.5 Xalkori
18. ALK Inhibitor - On Going Research & Development
18.1 Lorbrena Overcomes Xalkori as Front-Line Therapy in NSCLC
18.2 Comparable Time to Treatment Deterioration of Lorlatinib & Crizotinib in Patients with NSCLC
18.3 FDA Approved CDx Assay for Lorlatinib in ALK Positive NSCLC
18.4 TPX-0131 Overcomes ALK Mutations in Preclinical Models
19. ALK Inhibitor Drug Market Future Prospects
19.1 ALK Inhibitor Future Forecast
19.2 Future Market Opportunity of ALK Inhibitor
20. ALK Inhibitor Drug Market Dynamics
20.1 ALK Inhibitor Drug Market Favorable Parameters
20.2 Barriers to ALK Inhibitor Drug Market
21. Competitive Landscape
21.1 Astellas Pharma
21.2 AstraZeneca
21.3 Betta Pharmaceuticals
21.4 GlaxoSmithKline
21.5 Merck
21.6 Novartis
21.7 Pfizer
21.8 Roche
21.9 Takeda Pharmaceuticals
21.10 Turning Point Therapeutics
List of Figures
Figure 1-1: History of Anaplastic Lymphoma Kinase Inhibitors
Figure 2-1: Frequency of ALK Rearrangements by Cancer
Figure 2-2: Structure of Anaplastic Lymphoma Kinase (ALK) Gene
Figure 2-3: ALK - Potential Target in Cancer Therapy
Figure 2-4: Anaplastic Lymphoma Kinase Signaling Pathway
Figure 2-5: Crizotinib - Mechanism of Action
Figure 2-6: Alectinib - Mechanism of Action
Figure 3-1: Role of ALK Inhibitors in NSCLC
Figure 3-2: Approved ALK Inhibitors for NSCLC
Figure 3-3: Ongoing Trials with Combination Therapy in ALK-Rearranged NSCLCs
Figure 4-1: ALK Protein Structure & Mutations Found in Neuroblastoma
Figure 4-2: Clinical trials Evaluating ALK Inhibitors in Neuroblastoma
Figure 5-1: Clinical trials Evaluating ALK Inhibitors in Lyphoma
Figure 6-1: ALK Fusions in Renal Cell Carcinoma
Figure 7-1: Xalkori - FDA Approval by Indication
Figure 7-2: Xalkori - FDA Approval by Region
Figure 7-3: US - Sugen’s Xalkori Patent Issue & Expiration Year
Figure 7-4: US - Pfizer’s Xalkori Patent Issue & Expiration Year
Figure 7-5: US - Agouron’s Xalkori Patent Issue & Expiration Year
Figure 7-6: US - Price for 60 Capsule Supply & Price Per Unit of Xalkori Oral Capsule (US$), March’2021
Figure 7-7: UK - Price for 60 Capsule Supply & Price Per Unit of Xalkori Oral Capsule (US$/GBP), March’2021
Figure 7-8: Xalkori - Recommended & Reduced Daily Dose (mg)
Figure 7-9: Global - Xalkori Annual Sales (US$ Million), 2017 - 2020
Figure 7-10: US - Xalkori Annual Sales (US$ Million), 2017 - 2020
Figure 7-11: Global - Xalkori Annual Sales by Region (US$ Million), 2020
Figure 7-12: Global - Xalkori Annual Sales by Region (%), 2020
Figure 7-13: Global - Xalkori Quarterly Sales (US$ Million), 2019 & 2020
Figure 7-14: US - Xalkori Quarterly Sales (US$ Million), 2020
Figure 7-15: Europe - Xalkori Quarterly Sales (US$ Million), 2020
Figure 8-1: Zykadia - FDA Approval by Indication
Figure 8-2: Zykadia - FDA Approval Year by Region
Figure 8-3: US - Number of Zykadia Patents by Assignee
Figure 8-4: US - Novartis’s Zykadia Patent Issue & Expiration Year
Figure 8-5: US - Rigel’s Zykadia Patent Issue & Expiration Year
Figure 8-6: US - IRM’s Zykadia Patent Issue & Expiration Year
Figure 8-7: US - Price for 84 Tablets Supply & Price Per Unit of Zykadia Oral Tablet (US$), Mrch’2021
Figure 8-8: UK - Price for 84 Tablets Supply & Price Per Unit of Zykadia Oral Tablet (US$/GBP), March’2021
Figure 8-9: Zykadia - Recommended & Reduced Dose for NSCLC Treatment (mg per day)
Figure 9-1: Alsensa - FDA Approval by Indication
Figure 9-2: Alsensa - FDA Approval by Region
Figure 9-3: US - Alecensa Patent Issue & Expiration Year
Figure 9-4: US - Price for 240 Tablet Supply & Price Per Unit of Alecensa Oral Tablet (US$), March’2021
Figure 9-5: UK - Price for 224 Tablet Supply & Price Per Unit of Alecensa Oral Tablet (US$/GBP), March’2021
Figure 9-6: Alecensa - Recommended & Reduced Dose for NSCLC Treatment (mg per day)
Figure 9-7: Global - Alecensa Annual Sales (US$/CHF Million), 2017 - 2020
Figure 9-8: US - Alecensa Annual Sales (US$/CHF Million), 2017 - 2020
Figure 9-9: Europe - Alecensa Annual Sales (US$/CHF Million), 2018 - 2020
Figure 9-10: Japan - Alecensa Annual Sales (US$/CHF Million), 2017 - 2020
Figure 9-11: Global - Alecensa Annual Sales by Region (US$/CHF Million), 2020
Figure 9-12: Global - Alecensa Annual Sales by Region (%), 2020
Figure 9-13: Global - Alecensa Quarterly Sales (US$/CHF Million), 2019
Figure 9-14: Global - Alecensa Quarterly Sales (US$/CHF Million), 2020
Figure 9-15: US - Alecensa Quarterly Sales (US$/CHF Million), 2020
Figure 9-16: Europe - Alecensa Quarterly Sales (US$/CHF Million), 2020
Figure 9-17: Japan - Alecensa Quarterly Sales (US$/CHF Million), 2020
Figure 10-1: Alunbrig - FDA Approval by Indication
Figure 10-2: Alunbrig - FDA Approval Year by Region
Figure 10-3: Alunbirg - Patent Issue & Expiration Year
Figure 10-4: US - Price for 30 Tablets & Price Per Unit of 30mg Alunbirg Tablet (US$), March’2021
Figure 10-5: US - Price for Various Supplies of 90 mg Alunbirg Tablet (US$), March’2021
Figure 10-6: US - Price for 30 Tablets & Price Per Unit of 180mg Alunbirg Tablet (US$), March’2021
Figure 10-7: US - Price for 30 Tablets & Price Per Unit of 90-180mg Alunbirg Tablet (US$), March’2021
Figure 10-8: UK - Price for Various Supplies of Alunbirg Oral Tablet of 30mg (US$/GBP), March’2021
Figure 10-9: UK - Price for Various Supplies of Alunbirg Oral Tablet of 90mg (US$/GBP), March’2021
Figure 10-10: UK - Price for 28 Tablets & Price Per Unit Tablet of Alunbirg 180mg (US$/GBP), March’2021
Figure 10-11: UK - Price for 28 Tablets & Price Per Unit Tablet of Alunbirg 90mg-180mg (US$/GBP), March’2021
Figure 10-12: Alunbirg - Recommended & Reduced Dose (mg)
Figure 10-13: Global - Alunbrig Annual Sales (US$/JPY Million), 2018 - 2020
Figure 10-14: Global - Alunbrig Quarterly Sales (US$/JPY Million), 2019
Figure 10-15: Global - Alunbrig Quarterly Sales (US$/JPY Million), 2020
Figure 10-16: Global - Alunbrig Annual Sales by Region (US$/JPY Million), 2020
Figure 10-17: Global - Alunbrig Annual Sales by Region (%), 2020
Figure 10-18: US - Alunbrig Quarterly Sales (US$/JPY Million), 2020
Figure 11-1: Lorbrena - FDA Approval by Indication
Figure 11-2: Lorbrena - FDA Approval Year by Region
Figure 11-3: US - Lorbrena Patent Issue & Expiration Year
Figure 11-4: US - Price for 30 Tablet Supply & Price Per Unit of 25mg Lorbrena Oral Tablet (US$), March’2021
Figure 11-5: US - Price for 30 Tablet Supply & Price Per Unit of 100 mg Lorbrena Oral Tablet (US$), March’2021
Figure 11-6: UK - Price for 90 Tablets Supply & Price Per Unit of Lorbrena Oral Tablet of 25mg (US$/GBP), March’2021
Figure 11-7: UK - Price for 120 Tablets Supply & Price Per Unit of Lorbrena Oral Tablet of 25mg (US$/GBP), March’2021
Figure 11-8: UK - Price for 30 Tablets Supply & Price Per Unit of Lorbrena Oral Tablet of 100mg (US$/GBP), March’2021
Figure 11-9: Lorbrena - Recommended & Reduced Dose for NSCLC Treatment (mg per day), March’2021
Figure 11-10: Global - Lorbrena Annual Sales (US$ Million), 2019 & 2020
Figure 11-11: US - Lorbrena Annual Sales (US$ Million), 2019 & 2020
Figure 11-12: Europe - Lorbrena Annual Sales (US$ Million), 2019 & 2020
Figure 11-13: ROW - Lorbrena Annual Sales (US$ Million), 2019 & 2020
Figure 11-14: Global - Lorbrena Annual Sales by Region (US$ Million), 2020
Figure 11-15: Global - Lorbrena Annual Sales by Region (US$ Million), 2020
Figure 12-1: Ensartinib - Mechanism of Action
Figure 12-2: Clinical Trials using Ensartinib
Figure 13-1: Global - ALK Inhibitor Clinical Trials by Phase (Number of Drugs), 2021 Till 2026
Figure 13-2: Global - ALK Inhibitor Clinical Trials by Company (Number of Drugs), 2021 Till 2026
Figure 13-3: Global - ALK Inhibitor Clinical Trials by Country (Number of Trials), 2021 Till 2026
Figure 13-4: Global - ALK Inhibitor Clinical Trials by Patient Segment (Number of Trials), 2021 Till 2026
Figure 13-5: ALK Inhibitor Clinical Trials by Region
Figure 13-6: North America - ALK Inhibitor Clinical Trial by Region
Figure 14-1: Lung Cancer Incidences by Region (Million), 2020 & 2040
Figure 14-2: Global - Anaplastic Lymphoma Kinase Inhibitors Market Size (US$ Billion), 2017-2020
Figure 14-3: Global - Anaplastic Lymphoma Kinase Inhibitors Market Size (US$ Billion), 2021-2026
Figure 14-4: US - Anaplastic Lymphoma Kinase Inhibitors Market Size (US$ Million), 2017-2020
Figure 14-5: US - Anaplastic Lymphoma Kinase Inhibitors Market Size (US$ Million), 2019-2026
Figure 14-6: Europe - Anaplastic Lymphoma Kinase Inhibitors Market Size (US$ Million), 2020-2026
Figure 15-1: Global - First Generation ALK Inhibitor Market Size (US$ Million), 2017-2020
Figure 15-2: Global - First Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 15-3: ALK Inhibitor Drug Market by Product (%), 2020
Figure 15-4: ALK Inhibitor Drug Market by Product (%), 2026
Figure 15-5: US - First Generation ALK Inhibitor Market Size (US$ Million), 2017 - 2020
Figure 15-6: US - First Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 15-7: Europe - First Generation ALK Inhibitor Market Size (US$ Million), 2017 - 2020
Figure 15-8: Europe - First Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 15-9: First Generation ALK Inhibitor - Market Size by Region (%), 2020
Figure 15-10: Global - Second Generation ALK Inhibitor Market Size (US$ Million), 2018-2020
Figure 15-11: Global - Second Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 15-12: Second Generation ALK Inhibitor - Market Size by Product (%), 2020
Figure 15-13: US - Second Generation ALK Inhibitor Market Size (US$ Million), 2018-2020
Figure 15-14: US - Second Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 15-15: Second Generation ALK Inhibitor - Market Size by Region (%), 2020
Figure 15-16: Second Generation ALK Inhibitor - Market Size by Region (%), 2026
Figure 15-17: US - Alecensa Market Size (US$ Million), 2017 - 2020
Figure 15-18: US - Alecensa Market Size (US$ Million), 2021 - 2026
Figure 15-19: Europe - Alecensa Market Size (US$ Million), 2018 - 2020
Figure 15-20: Europe - Alecensa Market Size (US$ Million), 2021 - 2026
Figure 15-21: Alecensa - Market Size by Region (%), 2020
Figure 15-22: Global - Lorlatinib Market Size (US$ Million), 2019 & 2020
Figure 15-23: Global - Third Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 15-24: ALK Inhibitor Drug Market by Product (%), 2020
Figure 15-25: US - Lorlatinib Market Size (US$ Million), 2019 & 2020
Figure 15-26: US - Third Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 15-27: Europe - Lorlatinib Market Size (US$ Million), 2019 & 2020
Figure 15-28: Europe - Third Generation ALK Inhibitor Market Size (US$ Million), 2021-2026
Figure 18-1: Lorbrena - Risk of Tumor Progression (%)
Figure 18-2: Risk of Tumor Progression by Product (%)
Figure 19-1: Global - Tyrosine Kinase Inhibitor Market Size (US$ Billion), 2017-2020
Figure 19-2: Global - Tyrosine Kinase Inhibitor Market Size (US$ Billion), 2021-2026
Figure 19-3: Global - Anaplastic Lymphoma Kinase Inhibitor Market Size (US$ Billion), 2017-2020
Figure 19-4: Tyrosine Kinase Inhibitor Market by Type (%), 2020
Figure 19-5: Global - ALK Inhibitor Market Opportunity by 15% Tyrosine Kinase Inhibitor Market (US$ Billion), 2021-2026
Figure 19-6: Global - ALK Inhibitor Market Opportunity by 20% Tyrosine Kinase Inhibitor Market (US$ Billion), 2021-2026
Figure 19-7: Global - ALK Inhibitor Market Opportunity by 25% Tyrosine Kinase Inhibitor Market (US$ Billion), 2021-2026
Figure 19-8: Global - ALK Inhibitor Market Opportunity by 25% Tyrosine Kinase Inhibitor Market (US$ Billion), 2021-2026
Figure 19-9: Global - Tagrisso Market Size (US$ Billion), 2017-2020
Figure 19-10: Global - Alectinib Market Size (US$ Billion), 2021-2026
Figure 20-1: ALK Inhibitors Drug Market Favorable Parameters
Figure 20-2: Cancer Incidences by Region (Million), 2020 & 2040
Figure 20-3: Cancer Deaths by Region (Million), 2020 & 2040
Figure 20-4: Alunbrig - Average Cost of Daily, Monthly & Annual Cost of Treatment (US$), March’2021
Figure 20-5: Lorbrena - Average Cost of Daily, Monthly & Annual Cost of Treatment (US$), March’2021
Figure 20-6: Barriers to ALK Inhibitor Drug Market
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma
- AstraZeneca
- Betta Pharmaceuticals
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Roche
- Takeda Pharmaceuticals
- Turning Point Therapeutics
